Syngeneic Homograft of Framework Regions Enhances the Affinity of the Mouse Anti-human Epidermal Receptor 2 Single-chain Antibody E23sFv

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2021 Jan 18

PMID 33456503

Authors

Qing Ou-Yang

Jun-Lin Ren

Bo Yan

Jian-Nan Feng

An-Gang Yang

Jing Zhao

Affiliations

Soon will be listed here.

Abstract

e23sFv is a HER2-targeted single-chain variable fragment (scFV) that was characterized as the targeting portion of a HER2-targeted tumour proapoptotic molecule in our previous study. antibody affinity maturation is a method to enhance antibody affinity either by complementarity-determining region (CDR) mutagenesis or by framework region (FR) engraftment. In the present study, the affinity of e23sFv was enhanced using two strategies. In one approach, site-directed mutations were introduced into the FRs of e23sFv (designated EMEY), and in the other approach e23sFv FRs were substituted with FRs from the most homologous screened antibodies (designated EX1 and EX2). Notably, EX1 derived from the FR engraftment strategy demonstrated a 4-fold higher affinity for HER2 compared with e23sFv and was internalized into HER2-overexpressing cells; however, EMEY and EX2 exhibited reduced affinity for HER2 and decreased internalization potential compared with EX1. The 3D structure of EX1 and the HER2-EX1 complex was acquired using molecular homology modelling and docking and the HER2 epitopes of EX1 and the molecular interaction energy of the EX1-HER2 complex were predicted. In the present study, it was demonstrated that scFv affinity improvement based on sequence alignment was feasible and effective. Moreover, the FR grafting strategy was indicated to be more effective and simple compared with site-directed mutagenesis to improve e23sFv affinity. In conclusion, it was indicated that the affinity-improved candidate EX1 may present a great potential for the diagnosis and treatment of HER2-overexpressing tumours.

References

Kasprzyk P, Song S, Di Fiore P, King C . Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. 1992; 52(10):2771-6. View

Teplyakov A, Obmolova G, Malia T, Raghunathan G, Martinez C, Fransson J . Structural insights into humanization of anti-tissue factor antibody 10H10. MAbs. 2017; 10(2):269-277. PMC: 5825201. DOI: 10.1080/19420862.2017.1412026. View

Wright G, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec M, Bigler M . Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003; 171(6):3034-46. DOI: 10.4049/jimmunol.171.6.3034. View

Chothia C, Lesk A . Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol. 1987; 196(4):901-17. DOI: 10.1016/0022-2836(87)90412-8. View

Tahara T, Kuwaki T, Matsumoto A, Morita H, Watarai H, Inagaki Y . Neutralization of biological activity and inhibition of receptor binding by antibodies against human thrombopoietin. Stem Cells. 1998; 16(1):54-60. DOI: 10.1002/stem.160054. View

Jia L, Zhang L, Yu C, Zhao J, Xu Y, Gui J . Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res. 2003; 63(12):3257-62. View

LuCore S, Litman J, Powers K, Gao S, Lynn A, Tollefson W . Dead-End Elimination with a Polarizable Force Field Repacks PCNA Structures. Biophys J. 2015; 109(4):816-26. PMC: 4547145. DOI: 10.1016/j.bpj.2015.06.062. View

Sheedy C, MacKenzie C, Hall J . Isolation and affinity maturation of hapten-specific antibodies. Biotechnol Adv. 2007; 25(4):333-52. DOI: 10.1016/j.biotechadv.2007.02.003. View

Batra J, Kasprzyk P, Bird R, Pastan I, King C . Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci U S A. 1992; 89(13):5867-71. PMC: 49398. DOI: 10.1073/pnas.89.13.5867. View

10.

Rimawi M, Schiff R, Osborne C . Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28. DOI: 10.1146/annurev-med-042513-015127. View

11.

Yan B, Ouyang Q, Zhao Z, Cao F, Wang T, Jia X . Potent killing of HBV-related hepatocellular carcinoma by a chimeric protein of anti-HBsAg single-chain antibody and truncated Bid. Biomaterials. 2013; 34(20):4880-9. DOI: 10.1016/j.biomaterials.2013.03.046. View

12.

Moreira G, Fuhner V, Hust M . Epitope Mapping by Phage Display. Methods Mol Biol. 2017; 1701:497-518. DOI: 10.1007/978-1-4939-7447-4_28. View

13.

Tiller K, Chowdhury R, Li T, Ludwig S, Sen S, Maranas C . Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis. Front Immunol. 2017; 8:986. PMC: 5591402. DOI: 10.3389/fimmu.2017.00986. View

14.

Ou-Yang Q, Yan B, Li A, Hu Z, Feng J, Lun X . Construction of humanized anti-HER2 single-chain variable fragments (husFvs) and achievement of potent tumor suppression with the reconstituted husFv-Fdt-tBid immunoapoptotin. Biomaterials. 2018; 178:170-182. DOI: 10.1016/j.biomaterials.2018.06.016. View

15.

Prassler J, Steidl S, Urlinger S . In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology. Immunotherapy. 2010; 1(4):571-83. DOI: 10.2217/imt.09.23. View

16.

Foote J, Winter G . Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol. 1992; 224(2):487-99. DOI: 10.1016/0022-2836(92)91010-m. View

17.

Briney B, Sok D, Jardine J, Kulp D, Skog P, Menis S . Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell. 2016; 166(6):1459-1470.e11. PMC: 5018249. DOI: 10.1016/j.cell.2016.08.005. View

18.

Zhang L, Cai Q, Cai Z, Fang Y, Zheng C, Wang L . Interactions of Bovine Serum Albumin with Anti-Cancer Compounds Using a ProteOn XPR36 Array Biosensor and Molecular Docking. Molecules. 2016; 21(12). PMC: 6274227. DOI: 10.3390/molecules21121706. View

19.

Mazor R, Onda M, Pastan I . Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev. 2016; 270(1):152-64. PMC: 4758696. DOI: 10.1111/imr.12390. View